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Objectives: Dynamic changes in psychophysiological arousal are directly expressed
in the sympathetic innervation of the skin. This activity can be measured as tonic
and phasic fluctuations in electrodermal activity [Galvanic Skin Response (GSR)/skin
conductance]. Biofeedback training can enable an individual to gain voluntary control
over this autonomic response and its central correlates. Theoretically, control of
psychophysiological arousal may be harnessed as a therapy for epilepsy, to mitigate
pre-ictal states. Evidence is accumulating for the clinical efficacy of GSR biofeedback
training in the management of drug resistant epilepsy. In this review, we analyse current
evidence of efficacy with GSR biofeedback and evaluate the methodology of each study.
Method: We searched published literature pertaining to interventional studies of GSR
biofeedback for epilepsy, through MEDLINE and Cochrane databases (1950–2018).
Using percentage seizure reduction as an indicator of therapeutic efficacy induced by
GSR biofeedback, we used meta-analytic methods to summarize extant findings. We
also compare and contrast study design with relevance to the interpretation of outcomes.
Results: Out of 21 articles retrieved for GSR/EDA/Skin conductance biofeedback, four
studies were identified as interventional trials, involving 99 patients with drug-resistant
epilepsy in total. Three of these studies included a control group and a positive
therapeutic effect of biofeedback was reported in each of these. The difference in seizure
frequency percentage (Biofeedback—Control) was between−54.4 and−74.0% with an
overall weighted mean difference of −64.3% (95% CI: −85.4 to −43.2%). The response
rates (proportion of patients manifesting >50% reduction in seizure frequency) varied
from 45 to 66% across studies.
Significance: This timely evaluation highlights the potential value of GSR biofeedback
therapy, and informs the optimal study design of larger scale studies that are now
required to more definitively establish the utility of this non-invasive, non-pharmacological
interventional approach for drug-resistant epilepsy.
Keywords: epilepsy, biofeedback, galvanic skin response, skin conductance, electrodermal activity, autonomic
activity, behavioral therapy
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INTRODUCTION
Pharmacological therapy is the mainstay for the treatment of
epilepsy. However, about 30% of people with epilepsy are
drug-resistant and continue to have seizures despite optimal
medications (1). There are alternative treatment options
available for these patients, but these are limited to invasive
and costly neurosurgical procedures including resection, Vagus
Nerve Stimulation (VNS), Deep Brain Stimulation, and other
options such as dietary modification. Biofeedback approaches
offer non-invasive and likely cost-effective biobehavioral
interventions. There is accumulating proof-of-concept
evidence supporting biofeedback training as an efficacious
means of reducing seizures in patients with drug resistant
epilepsy (2–4).
Biofeedback training provides people with epilepsy a tool
to learn how to voluntarily control usually-autonomous
physiological signals: By providing conscious access to covert
responses, an individual can learn to increase or decrease a
physiological signal at will. Galvanic Skin Response (GSR)
is an “electrodermal” signature of the sympathetic nervous
innervation of the skin (5). GSR can be measured on the skin
surface and predominantly reflects the unopposed action of
sudomotor sympathetic nerves on secretory channels of eccrine
sweat glands: enhanced porosity increases electrical conductance.
GSR is familiar to many as the signal used in “lie detectors,”
since GSR amplitude reacts sensitively to emotional provocation,
salient thoughts, and attentional demand. Correspondingly, this
effect exemplifies the direct coupling between sympathetic sweat
gland innervation, measured by GSR, and brain states of affective
and cognitive arousal.
Development
Research into the effect of GSR biofeedback therapy on
epilepsy was initiated by Nagai in 1997. The methodology
was established through a series of neuroscientific studies,
initially in healthy participants. The first published study,
underpinning current GSR biofeedback methodology,
described the relationship between peripheral autonomic
activity and cortical excitation (6). Here, GSR amplitude was
observed to inversely predict an encephalographic (EEG)
index of cortical excitation; i.e., slow cortical potentials
where there is a direct current (DC) shift within the EEG.
Such DC shifts often precede epileptic seizures (7–9).
Consequently, it was hypothesized that enhancement of
peripheral sympathetic activity using GSR biofeedback may
suppress the pre-ictal DC shift; this provided the rationale for the
therapeutic use of GSR biofeedback training to reduce epileptic
seizures (6).
The first clinical trial was conducted using a randomized
controlled trial (RCT) design including a sham control (10).
It is rarely possible to implement a full and effective double-
blinding of behavioral (and cognitive) interventions without
Abbreviations:DMN, default mode network; EEG, electroencephalography; GSR,
galvanic skin response;MPFC,medial prefrontal cortex; OFC, orbitofrontal cortex;
TLE, temporal lobe epilepsy; VNS, vagus nerve stimulation.
significantly compromising the logistics of delivering the therapy.
Nevertheless, this study demonstrated a significant reduction in
seizure frequency with a response rate of 60% controlling for
non-specific effects of therapist contact. The efficacy of GSR
biofeedback has since been replicated in three studies (11–13).
Known Neural Mechanisms
The neural mechanisms through which GSR biofeedback
might influence seizure thresholds were investigated in parallel
with this first clinical trial. Three neuroimaging/EEG studies
were conducted to characterize the detailed actions of GSR
biofeedback on brain function. GSR biofeedback was observed to
modulate activity across cortical and subcortical brain regions.
Strikingly, however, activity within medial prefrontal cortex
(MPFC) and orbitofrontal cortex (OFC) demonstrated a strong
inverse correlation with tonic GSR (skin conductance levels) (14).
These paralimbic cortices (MPFC and OFC) form a part of the
default mode network; DMN (15). Abnormalities in functional
activity and connectivity within the DMN have been reported in
patients with epilepsy and associate with loss of consciousness
during seizures (16, 17). Thus, repeated modulation of MPFC
and OFC with GSR biofeedback training might influence the
functional dynamics of this “consciousness” network.
A parallel neuroimaging study (18) also demonstrated that
cortical arousal, reflected in the generation of slow cortical
potentials during sensorimotor anticipation, is underpinned by
activity within thalamus, cingulate cortex and supplementary
motor area (SMA). Moreover, both healthy participants and
patients with epilepsy demonstrate a reduced amplitude of
(induced) slow cortical potentials after a course of GSR
biofeedback training to increase sympathetic activity (6, 19).
Together these studies linked changes in peripheral and central
arousal to functional shifts within cortical and subcortical
brain networks.
Lastly, a neuroimaging study in patients undergoing GSR
biofeedback training confirmed that reduction of seizures is
indeed linked to neural network changes involving the OFC
(13): Here, GSR biofeedback training strengthened the functional
connectivity between the OFC and the right amygdala. The
degree of the functional connectivity changes was related to the
reduction of patients’ seizure frequency, such that patients who
achieved greater right amygdala-OFC functional connectivity
demonstrated a larger reduction in seizure frequency after 1
month of GSR biofeedback training. Psychological outcomes
(reductions in anxiety and depression) did not account for either
the seizure reduction (11–13), or functional connectivity changes
(13). This indicates that changes in mental health states (such as
anxiety and depression) are not necessarily direct contributing
factors in reducing seizures. However, the positive correlation
between increased fronto-limbic functional connectivity and
degree of seizure reduction is worth further investigation. The
amygdala and OFC form a physical white matter pathway, the
uncinate fasciculus, thus repeated modulation of MPFC and
OFC with GSR biofeedback training may also alter emotional
cognition. Taken together these studies provide strong proof-of-
concept support and validation for GSR biofeedback training as
a promising approach to epilepsy management.
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Other Biofeedback Therapies in Epilepsy
The first application of biofeedback to epilepsy was in 1970
using EEG as a physiological parameter (20, 21). The feedback
parameters of EEG biofeedback were broadly categorized into
(1) enhancement of sensorimotor rhythms, which are considered
to regulate thalamo-cortical circuitry (20), and (2) regulation
of slow cortical potentials, which modulate cortical excitability
(22). A meta-analysis of EEG biofeedback on epilepsy that
included 10 studies reported more than 70% of participants
achieved fewer seizures after EEG biofeedback training (4). The
focus of this systematic review/meta-analysis is another type
of biofeedback using GSR, the clinical effects of which appear
more quickly following a less complicated procedure compared
to EEG biofeedback.
Objectives
In this systematic review, we compared studies from the
perspectives of participant recruitment, intervention, outcomes,
and study designs to evaluate the efficacy of GSR biofeedback
therapy in reducing seizure frequency in people with drug
resistant epilepsy. The objective of this article is also to
draw together current evaluations of GSR biofeedback training
efficacy to inform next-stage investigations and potential clinical
introduction of a non-pharmacological intervention for drug
resistant epilepsy.We also aim to guide optimal design of a future
clinical trial.
MATERIALS AND METHODS
The methods used in this review follow the guidance of the
PRISMA statement (2009) (23).
Search Method and Data Collection
We searched the published literature using Medline and
Cochrane Library using the terms (“epilepsy” OR “seizures”)
AND “biofeedback” AND (“galvanic skin response” OR
“Electrodermal activity” OR “skin conductance”) published in
English between 1st January 1950 and 31st July 2018. The article
titles and abstracts were screened by YN and CIJ. The reports
consisted of research papers, review articles and commentaries.
The process of study selection is described in Figure 1.
Inclusion and Exclusion Criteria
Only studies published in peer reviewed journals were selected.
Articles were eligible for inclusion if they were interventional
trials of GSR biofeedback to increase sympathetic activity. All
non-interventional and follow-up studies were excluded. One
study (24), exploring an effect of decreasing sympathetic activity,
was also excluded from the formal analysis, however a description
of the study is presented in the Table 1 for information.
Data Analysis
The primary outcome of interest in this review is the percentage
difference in seizure frequency change between the control and
biofeedback groups, where percentage seizure frequency change
= (Post-averaged seizure frequency—baseline averaged seizure
frequency)/baseline averaged seizure frequency× 100. The mean
FIGURE 1 | Flow chart of study selection.
and SD of the change in seizure frequency for the individual
control and biofeedback groups were collected from each study
(in duplicate by CIJ and YN) and the weighted mean percent
seizure frequency change was calculated individually for each
group, using all available data. The weighted mean percentage
difference, was then calculated for the studies that included both
a control group and biofeedback group. Fixed effect models were
fitted in Stata 15.1 using the metan command with the Mantel-
Haenszel method. Fixed effects models were used due to the
limited number of available studies. I2 was calculated where
appropriate to estimate the percentage of variation that was
due to heterogeneity between studies. In order to synthesize the
evidence for the efficacy of the intervention, the study procedures
of each articles were investigated in line with the PRISMA
statement (23). The bias report was independently written by CIJ
and reviewed by AS, neither of whom had conflicting interests in
the study outcomes.
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TABLE 1 | Study details.
Study Study design Epilepsy
types
No of
patients
Age/gender Protocol Length of
intervention
Outcome measures
Nagai et al., (10) RCT, single blinded, sham
control
Varied N = 21
B: 10
C: 8
Pilot: 3
16–60
M: 9
F: 9
Increase
sympathetic
activity
1 month Seizure frequency,
GSR change
Micoulaud-Franchi
et al. (11)
Open study TLE N = 11 18–60
M: 2
F: 9
Increase
sympathetic
activity
3 months Seizure frequency,
GSR change,
Psychological/cognitivemeasures
Scrimali et al. (24) Case study Brain
malformation
on right side
N = 1 NA Decrease
sympathetic
activity
24 months Seizure frequency,
Kotwas et al. (12) Controlled, single blinded TLE N = 30
B: 15
C: 15
18–65
M: 10
F: 20
Increase
sympathetic
activity
3 months Seizure frequency,
GSR change,
Psychological/cognitivemeasures
Nagai et al. (13) Controlled, semi RCT, single
blinded
TLE N = 40
B: 20
C: 20
18–70
M: 16
F: 24
Increase
sympathetic
activity
1 month Seizure frequency,
fMRI (functional connectivity
changes),
Psychological measures
RESULTS
Description of the Studies
Search Outcome
The electronic search found 221 articles. After eliminating 200
articles on the basis of relevance, 21 articles were left, of which 11
(52%) were research studies. Six studies were eventually selected
as interventional studies, however one article was removed as the
GSR biofeedback was provided with an atypical, instruction for
biofeedback. Another study was a follow-up report on long-term
effect of the intervention, which was again not analyzed but was
included in discussion. This left four interventional studies of
GSR biofeedback training in which the intervention was designed
to increase sympathetic activity.
Participants
All studies investigated adult patients with drug resistant epilepsy
(failure to respond to at least two appropriate anti-epileptic
drugs). Three of the four studies focused on patients with
temporal lobe epilepsy (TLE) (11–13). The average age of patients
were similar, with slight differences reflecting differences in the
age inclusion criteria. Themean baseline seizure frequencies were
also similar between all studies. The gender ratio was not equal.
Two studies recruited significantly more female, compared to
male, patients. The brief characteristics of the participants from
eligible studies are described in Table 1.
Study Designs
In chronological order, the first study (10) was a RCT, with a sham
control condition. This study investigated 18 patients with drug
resistant epilepsy (n = 10: therapy active group, n = 8: sham
control group). The second (11) was an open-label study on 11
patients with TLE. The third study (12) was a controlled, non-
randomized trial with 30 patients (n = 15: therapy active group,
n= 15: treatment as usual group). The fourth (13) study was also
a controlled trial with 40 patients with epilepsy (n = 20: therapy
active group, n = 20: treatment as usual group) with partial
randomization (deviation of 15%). These details are summarized
in Table 1.
Therapy Protocols
All selected clinical trials delivered active therapy in the form of
a face-to-face behavioral intervention. The pre- and post- seizure
frequencies were recorded for 3 months in all trials. In two trials
(10, 13), the intervention was provided in three sessions a week
(each 30min training duration), over 4 weeks. In contrast, the
other studies (11, 12) provided 1 h sessions of the intervention
once a week for 12 weeks. In all studies, GSR biofeedback was
given to increase sympathetic activity. “Positive” visual feedback
was given to indicate the desired direction of GSR amplitude
change and was used by patients to voluntarily learn to control
this index of alertness.
Study Quality
Blinding
None of the studies were fully double-blinded, consistent
with intrinsic difficulties in ensuring blindedness of behavioral
therapies. However, key aspects of this problem were mitigated
by allocating a follow-up assessor who was blinded to group
membership in the last study (13).
Participants’ Group Allocation
The first study (10) took the form of RCT, using a randomization
table. The fourth study (13) also attempted full randomization
as RCT, however this was not possible to achieve practically due
to geographical considerations that affected logistics of patients’
travel to the institution to receive behavioral therapy three times
per week. Deviation from full randomization affected 15% of
the participants. There is no mention of how participants were
allocated in the third study (12), thus selection bias cannot
be discounted.
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Attrition
The first and fourth studies (10, 13) describe drop-out rates
for patients and the data were analyzed using intention-to-treat
analysis. There was no attrition reported in the other two studies.
Meta-Analysis of Individual Study Results
Seizure Frequency Change
In each of the studies, percentage seizure frequency change
was calculated for each group from the patients’ seizure
frequencies (see methods), before and after control or
biofeedback intervention. In the three studies including a
control group, the average percentage frequency change in each
control group was positive (i.e., more seizures), but all included
0 (no change) within their 95% confidence intervals (Figure 2).
The weighted estimate of the percentage seizure frequency
change across the control groups was 17.5% with 95% CI −0.6
to 35.7%, indicating no improvement (i.e., no reduction) in the
patients’ seizure frequency after receiving a control intervention.
In each of the active biofeedback groups of the four studies, the
percentage seizure frequency changes were negative (i.e., fewer
seizures) with 0 outside their 95% confidence intervals. This
mean reduction in seizure frequency was consistent between
studies, between −43.0 and −49.3%. The weighted estimate
across the four biofeedback groups was −46.4% with 95% CI
−54.6 to−38.3%, indicating a reduction in seizure frequency for
patients after receiving a biofeedback intervention (Figure 2).
The weighted mean differences in seizure frequency change
between the control and biofeedback groups in the three studies
that included both groups were negative with 0 outside their 95%
confidence intervals (Figure 3). This difference was consistent
between studies, between −54.4 and −74.0%. The weighted
mean difference across the three studies was −64.3% with 95%
CI −85.4 to −43.2%, indicating a reduction in seizure frequency
for patients receiving a biofeedback intervention compared to
the control intervention. It is worth noting that there was an
overall increased seizure frequency in the control group in all
controlled studies, presumably reflecting natural fluctuation of
seizure frequency.
GSR Change
The analysis of GSR was conducted in three of the four studies
(10–12). Each study demonstrated a significant correlation
between GSR amplitude and seizure frequency change: the range
of correlation was between 0.54 and 0.74.
Additional Analysis
Three studies (11–13) investigated alterations in secondary
psychological outcomes and how these were related to changes
in seizure frequency. Although there were observed changes in
patient scores on psychological questionnaires measuring levels
of anxiety and depression, no correlations were consistently
found between these questionnaires and seizure frequency
changes. Two studies (11, 12) also administered cognitive tasks
to investigate the effect of the therapy on emotional processes
by presenting emotional stimulation. However, no clear effect
of the GSR biofeedback intervention was observed on cognitive
outcomes, demonstrating no difference between therapy and
control groups. One study (13) investigated functional neural
connectivity changes before and after the GSR biofeedback.
This study identified increased functional connectivity between
the right amygdala and OFC was linked to reduction of
seizure frequency.
DISCUSSION
This systematic review describes effects of GSR biofeedback
on reducing epileptic seizures in patients with drug resistant
epilepsy. Four interventional studies examined a total of 99
patients (56 in biofeedback groups). All studies demonstrated
a reduction in seizure frequency through biofeedback training
to increase sympathetic activity. This review also identified
differences in study procedures that impact interpretation of the
results as therapy outcomes and can inform the design of large-
scale trials of the utility and cost effectiveness of the therapy in
clinical settings.
Summary of Evidence
The principal outcome of this systematic review is the support of
evidence that GSR biofeedback training (to enhance sympathetic
activity) is a potentially effective therapeutic tool to reduce
epileptic seizures. Few studies have yet been conducted in this
area, but of particular note was the consistency of the beneficial
effect observed in patients with drug resistant epilepsy between
studies (weighted estimate of −46.4% with 95% CI −54.6 to
−38.3%). The magnitude of this effect is similar to that of other
interventions for epilepsy, e.g., new anti-epileptic drugs 21–
47% (25), VNS 30–70% (26) and ketogenic diets 30–55% (27).
Despite the encouraging overall outcome of this non-invasive
behavioral intervention, interpretations of the effect need to be
made with caution, not least in consideration of the differences
in design between studies. Out of three controlled trials, only
one study was conducted using both a fully randomized and
sham controlled design. All three trials with controls were single
blinded. Thus, none of the studies can robustly eliminate the
bias from expectation of therapists or patients. This is, however,
a general problem for all behavioral therapies: blindedness
is certainly one issue that has yet to be overcome when
characterizing the core effect of GSR biofeedback therapy. Full
randomization was attempted in two studies. However, this was
modified in one study on logistical grounds. This highlights
another difficulty associated with conducting pharmacological-
style RCTs in behavioral therapies, since the study often demands
that patients repeatedly travel to attend appointments for delivery
of the active therapy in contrast to treatment-as-usual controls.
While the intervention impacted positively on seizure
frequency, there was no correlation between seizure reduction
and changes in patients’ reported psychological states. In the trial
that used neuroimaging (13), fronto-limbic connectivity changes
predicted seizure reduction, however this functional connectivity
changes were not correlated with changes in mood symptoms.
Thus, the enhanced seizure control is putatively brought about
by better integration of central arousal with visceromotor
regulation (10) through a tonic modulation of amygdala—
OFC coherence. However, these effects on therapeutic outcome
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FIGURE 2 | Forrest plot of the seizure frequency change within each group for each study. I2-values indicate there was low heterogeneity between studies.
FIGURE 3 | Forrest plot of the difference in seizure frequency change between control and intervention groups. The I2-value indicates there was low heterogeneity
between studies.
were not mediated by subjective emotional states. This suggests
that GSR biofeedback training can impact on pathological
changes within the brain and low-level neural processes possibly
supporting a core effect, rather than exerting therapeutic action
such as a placebo response.
In comparison with themeta-analysis of EEG biofeedback, the
GSR biofeedback studies were generally more robust than those
on EEG biofeedback, where nine out of ten studies recruited
fewer than 10 patients for open (non-controlled) interventions
(4). The efficacies of GSR or EEG biofeedback appear similar
however, as over 70% of participants demonstrated reduction
of seizures in both meta-analyses. It is also worth mentioning
that efficacy of GSR biofeedback can be observed as early
as at 2 weeks of training, on the other hand, the standard
training duration with EEG biofeedback is between 6 weeks and
6 months (3).
Overall, our literature analysis revealed the usefulness of GSR
biofeedback in epilepsy. There is a paucity of therapeutic usage
of GSR in clinical settings, although GSR is frequently used
as a parameter of bodily arousal and increased attention in
psychological studies. It is expected that this informative and
easy to use autonomic parameter will be worthy of further
investigation in terms of its interaction with central functions and
with the other autonomic parameters.
Limitations and Future Trial
The number of published studies using GSR biofeedback
available for this systematic review was limited. Even
compared to studies using electroencephalography biofeedback
(neurofeedback), there is a paucity of studies utilizing (the
more accessible) GSR biofeedback as a behavioral intervention.
There is also little to indicate reporting bias, with unsuccessful
applications going unpublished. Despite this limitation, this
therapeutic approach appears promising. Future studies require
more stringent and standardized study designs to affirm clinical
efficacy in reducing epileptic seizures. Thus, at this stage,
this systematic review provides valuable insight for planning
such clinical trials. Across behavioral therapies, the issue of
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how to ensure blindness is a frequent focus of discussion
for such trials. Similar issues apply to surgical interventions;
since a clinician is actively responsible for delivering the
intervention, this constrains the installation of double-blinded
designs that are the gold-standard for pharmacological trials.
However, technological advances can potentially circumvent
this limitation. Digital technology with computerized and
online platforms for the therapy may represent a viable
alternative to face-to-face therapy that will not only permit
double blinded studies, but may broaden access and reduce
cost, enabling delivery of an effective non-drug treatment in
pharmaco-resistant epilepsy.
CONCLUSION
Despite the above limitations, this systematic review supports
a view that modulation of sympathetic activity using GSR
biofeedback represents a promising new therapeutic tool
for management of seizures in patients with epilepsy. For
future clinical trials, important elements to be considered
include size of patient population, seizure type, double-
blinding, inclusion of an appropriate control group, and robust
randomization methods.
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